Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
bristol-myers squibb
clinical trials
life sciences
national blog main
national top stories
new york blog main
new york top stories
nonalcoholic steatohepatitis
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
gilead sciences
indiana blog main
indiana top stories
johnson & johnson
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
aducanumab
affordable care act
alzheimer's disease
bayer
biogen
biotech
cancer
What
drug
4
×
nash
4
×
bio
news
roundup
approved
biogen’s
companies
disease
fatty
known
liver
new
aducanumab
alzheimer’s
amyloid
angst
approval
bagged
billions
biogen
biopharmaceutical
brammer
convo
data
digital
earlier
effects
epidemic
failure
failures
fda
felt
frenzied
growing
horizon
intercept
led
littered
lost
Language
Current search:
nash
×
drug
×
@xconomy.com
4 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug